I. Halstead Michael's most recent trade in Intra-Cellular Therapies Inc was a trade of 13,133 Restricted Stock Units done . Disclosure was reported to the exchange on March 6, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| IntraCellular Therapies Inc | Michael I. Halstead | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 13,133 | 13,133 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 13,133 | 24,437 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 7,345 | 25,064 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 7,345 | 0 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.19 per share. | 06 Mar 2025 | 6,718 | 17,719 (0%) | 0% | 131.2 | 881,334 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 131.24 per share. | 06 Mar 2025 | 3,757 | 21,307 (0%) | 0% | 131.2 | 493,069 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 12,239 | 17,565 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2025 | 12,239 | 24,478 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 128.20 per share. | 01 Mar 2025 | 6,261 | 11,304 (0%) | 0% | 128.2 | 802,660 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 45,454 | 45,454 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 11,017 | 11,017 (0%) | 0% | 0 | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 127.00 per share. | 31 Jan 2025 | 5,691 | 5,326 (0%) | 0% | 127 | 722,757 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.94 per share. | 12 Nov 2024 | 22,869 | 22,869 (0%) | 0% | 23.9 | 547,484 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2024 | 22,869 | 0 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2024 | 18,714 | 0 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.89 per share. | 12 Nov 2024 | 18,714 | 18,714 (0%) | 0% | 36.9 | 690,359 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Sale of securities on an exchange or to another person at price $ 88.72 per share. | 12 Nov 2024 | 15,105 | 7,764 (0%) | 0% | 88.7 | 1,340,116 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Sale of securities on an exchange or to another person at price $ 88.17 per share. | 12 Nov 2024 | 13,371 | 5,343 (0%) | 0% | 88.2 | 1,178,921 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Sale of securities on an exchange or to another person at price $ 89.63 per share. | 12 Nov 2024 | 6,116 | 1,648 (0%) | 0% | 89.6 | 548,177 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Sale of securities on an exchange or to another person at price $ 88.92 per share. | 12 Nov 2024 | 5,343 | 0 (0%) | 0% | 88.9 | 475,100 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | President | Sale of securities on an exchange or to another person at price $ 90.89 per share. | 12 Nov 2024 | 1,648 | 0 (0%) | 0% | 90.9 | 149,787 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 66.14 per share. | 07 Mar 2024 | 12,912 | 220 (0%) | 0% | 66.1 | 854,000 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 7,345 | 7,345 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2024 | 7,345 | 7,345 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 65.82 per share. | 07 Mar 2024 | 6,107 | 1,238 (0%) | 0% | 65.8 | 401,963 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 66.70 per share. | 07 Mar 2024 | 1,238 | 0 (0%) | 0% | 66.7 | 82,575 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 66.81 per share. | 07 Mar 2024 | 220 | 0 (0%) | 0% | 66.8 | 14,698 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 13,132 | 26,266 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 13,132 | 13,132 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 36,717 | 36,717 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael Halstead I. | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,907 | 7,907 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael Halstead I. | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 7,907 | 0 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | I. Halstead Michael | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 69.54 per share. | 23 Feb 2024 | 7,215 | 392 (0%) | 0% | 69.5 | 501,731 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 70.13 per share. | 23 Feb 2024 | 392 | 0 (0%) | 0% | 70.1 | 27,491 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 68.54 per share. | 23 Feb 2024 | 300 | 7,607 (0%) | 0% | 68.5 | 20,562 | Common Stock |
| IntraCellular Therapies Inc | I. Michael Halstead | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 11,860 | 11,860 (0%) | 0% | 0 | Common Stock | |
| IntraCellular Therapies Inc | I. Halstead Michael | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 66.37 per share. | 01 Feb 2024 | 11,146 | 714 (0%) | 0% | 66.4 | 739,760 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 67.17 per share. | 01 Feb 2024 | 714 | 0 (0%) | 0% | 67.2 | 47,959 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.73 per share. | 11 Jan 2024 | 46,115 | 46,115 (0%) | 0% | 12.7 | 587,044 | Common Stock |
| IntraCellular Therapies Inc | Michael Halstead I. | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2024 | 46,115 | 0 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | I. Halstead Michael | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 67.10 per share. | 11 Jan 2024 | 30,360 | 1,486 (0%) | 0% | 67.1 | 2,037,156 | Common Stock |
| IntraCellular Therapies Inc | Michael Halstead I. | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 66.31 per share. | 11 Jan 2024 | 18,154 | 31,846 (0%) | 0% | 66.3 | 1,203,792 | Common Stock |
| IntraCellular Therapies Inc | Michael Halstead I. | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2024 | 3,885 | 22,869 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Halstead I. Michael | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.94 per share. | 11 Jan 2024 | 3,885 | 50,000 (0%) | 0% | 23.9 | 93,007 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 67.80 per share. | 11 Jan 2024 | 1,486 | 0 (0%) | 0% | 67.8 | 100,751 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 16,708 | 16,708 (0%) | 0% | 0 | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 43.20 per share. | 09 Mar 2023 | 14,208 | 2,500 (0%) | 0% | 43.2 | 613,786 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 7,344 | 14,690 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2023 | 7,344 | 7,344 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 44.99 per share. | 09 Mar 2023 | 6,868 | 476 (0%) | 0% | 45.0 | 308,991 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 42.52 per share. | 09 Mar 2023 | 2,500 | 0 (0%) | 0% | 42.5 | 106,300 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 44.15 per share. | 09 Mar 2023 | 476 | 0 (0%) | 0% | 44.1 | 21,015 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 39,398 | 39,398 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 47.03 per share. | 23 Feb 2023 | 7,906 | 0 (0%) | 0% | 47.0 | 371,819 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 7,906 | 7,907 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 7,906 | 7,906 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 11,139 | 11,139 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 11,139 | 0 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 46.56 per share. | 18 Feb 2023 | 9,296 | 1,843 (0%) | 0% | 46.6 | 432,822 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 48.68 per share. | 18 Feb 2023 | 1,100 | 100 (0%) | 0% | 48.7 | 53,548 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 47.23 per share. | 18 Feb 2023 | 643 | 1,200 (0%) | 0% | 47.2 | 30,369 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 49.60 per share. | 18 Feb 2023 | 100 | 0 (0%) | 0% | 49.6 | 4,960 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2022 | 50,000 | 15,164 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.47 per share. | 01 Dec 2022 | 50,000 | 50,000 (0%) | 0% | 15.5 | 773,500 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 53.94 per share. | 01 Dec 2022 | 27,204 | 22,796 (0%) | 0% | 53.9 | 1,467,384 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 53.48 per share. | 01 Dec 2022 | 22,796 | 0 (0%) | 0% | 53.5 | 1,219,130 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 22,034 | 22,034 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 17,916 | 17,916 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 11,139 | 11,139 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 11,139 | 11,139 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 55.69 per share. | 18 Feb 2022 | 6,589 | 4,550 (0%) | 0% | 55.7 | 366,941 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 54.98 per share. | 18 Feb 2022 | 4,550 | 0 (0%) | 0% | 55.0 | 250,159 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2022 | 19,639 | 19,639 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2022 | 19,639 | 0 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 40.81 per share. | 08 Jan 2022 | 12,755 | 4,380 (0%) | 0% | 40.8 | 520,532 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 40.12 per share. | 08 Jan 2022 | 4,380 | 0 (0%) | 0% | 40.1 | 175,726 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 41.74 per share. | 08 Jan 2022 | 2,504 | 17,135 (0%) | 0% | 41.7 | 104,517 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 47.84 per share. | 21 Dec 2021 | 104,775 | 49,468 (0%) | 0% | 47.8 | 5,012,436 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 88,146 | 0 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.57 per share. | 21 Dec 2021 | 88,146 | 113,146 (0%) | 0% | 17.6 | 1,548,725 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 63,717 | 0 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.73 per share. | 21 Dec 2021 | 63,717 | 176,863 (0%) | 0% | 15.7 | 1,002,268 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 46.87 per share. | 21 Dec 2021 | 36,434 | 13,034 (0%) | 0% | 46.9 | 1,707,662 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2021 | 25,000 | 0 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.86 per share. | 21 Dec 2021 | 25,000 | 25,000 (0%) | 0% | 13.9 | 346,500 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 48.62 per share. | 21 Dec 2021 | 22,620 | 154,243 (0%) | 0% | 48.6 | 1,099,784 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 45.74 per share. | 21 Dec 2021 | 8,690 | 4,344 (0%) | 0% | 45.7 | 397,481 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 44.87 per share. | 21 Dec 2021 | 4,344 | 0 (0%) | 0% | 44.9 | 194,915 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 23,719 | 23,719 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2021 | 18,714 | 18,714 | - | - | Stock Option (right to buy) | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 11,139 | 11,139 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2021 | 11,139 | 22,278 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 39.28 per share. | 18 Feb 2021 | 10,039 | 1,100 (0%) | 0% | 39.3 | 394,332 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 38.91 per share. | 18 Feb 2021 | 1,100 | 0 (0%) | 0% | 38.9 | 42,801 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 19,638 | 19,639 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 19,638 | 19,638 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 32.07 per share. | 08 Jan 2021 | 17,702 | 1,936 (0%) | 0% | 32.1 | 567,703 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 31.65 per share. | 08 Jan 2021 | 1,936 | 0 (0%) | 0% | 31.6 | 61,274 | Common Stock |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 16,160 | 0 | - | - | Restricted Stock Units | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2021 | 16,160 | 16,160 (0%) | 0% | - | Common Stock | |
| IntraCellular Therapies Inc | Michael I. Halstead | EVP and General Counsel | Sale of securities on an exchange or to another person at price $ 31.39 per share. | 03 Jan 2021 | 12,986 | 3,174 (0%) | 0% | 31.4 | 407,631 | Common Stock |